MedPath

Anatomy-Based Fitting in Unexperienced Cochlear Implant Users

Not Applicable
Recruiting
Conditions
Sensorineural Hearing Loss
Cochlear Implants
Registration Number
NCT05451628
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

Severe to profound hearing loss affects 0,8% of the global population. For these people, a conventional hearing aid often does not provide sufficient benefit. However, these people can benefit from a cochlear implant (CI). A CI needs to be individually programmed (fitted) for each recipient. A fitting "map" is defined as a set of electrical parameters that are individually adapted to a recipient's needs to achieve optimal sound perception. At present, most CI recipients are fitted with a default frequency allocation map that doesn't take individual variability in size and shape of the cochlea into account. In this study, a fitting strategy based on the post-operative CT scan, that will allow the audiologist to set a frequency-band distribution for CI fitting that may be more closely aligned to the natural tonotopic frequency distribution of a normal hearing cochlea, will be evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Age ≥ 18 years
  • Post-lingual onset of severe to profound sensory-neural hearing loss in the implanted ear(s)
  • Post-operative Computed Tomography (CT) scan of the CI electrode available
  • Pre-operative result of pure-tone audiometry, speech test in quiet and in noise available
  • Subject implanted with MED-EL cochlear implant(s)
  • Subjects received a Flex28, FlexSoft or Standard electrode
  • Subject planned to receive a SONNET 2 or RONDO 3 audio processor on the newly implanted side
  • Audio processor not yet activated on the newly implanted side
  • The most apical active electrode contact has to be inserted at least 450°
  • Minimum of 10 active channels can be activated
  • Fluent in the language of the test centre
  • Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure
Exclusion Criteria
  • Lack of compliance with any inclusion criteria
  • Electric Acoustic Stimulation (EAS) user (user of an EAS audio processor)
  • Implanted with C40+, C40X and C40C
  • Implanted with an Auditory Brainstem Implant (ABI) or Split electrode array
  • Anything that, in the opinion of the Investigator, would place the subject at increased risk or pre-clude the subject's full compliance with or completion of the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Speech recognition test in quiet (S0): percentage correctly identified phonemes6 months post-activation
Secondary Outcome Measures
NameTimeMethod
Result of the pitch matching test: frequency differences in semitones6 months post-activation
Result of the perception of timbre test: Score on Visual Analog Scale (VAS)6 months post-activation

Patients have to rate the timbre on a visual analog scale (VAS) ranging from 0 to 10, where a higher score reflects a better outcome.

Result of the consonance and dissonance rating test: Plot of pleasantness over frequency interval and modulation measure6 months post-activation
Patient reported outcome- Hearing Implant Sound Quality Index (HISQUI): Total score and classification of self-perceived auditory benefit6 months post-activation
Speech recognition test in noise (S0N0): the speech reception threshold in dB SNR6 months post-activation
Result of the pitch matching test: frequency difference in semitones3 months post-activation
Result of the speech contrast discrimination test: Psychometric function of phoneme categorization6 months post-activation
Datalogging data: Average numbers of hours per day6 months post-activation

Trial Locations

Locations (1)

UZ Brussel

🇧🇪

Brussel, Belgium

UZ Brussel
🇧🇪Brussel, Belgium
Vedat Topsakal, Prof
Contact
Emilie Heuninck
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.